Doherty J F, Sadiq A D, Bayo L, Alloueche A, Olliaro P, Milligan P, von Seidlein L, Pinder M
Medical Research Council Laboratories, Banjul, The Gambia.
Trans R Soc Trop Med Hyg. 1999 Sep-Oct;93(5):543-6. doi: 10.1016/s0035-9203(99)90376-0.
Artemisinin derivatives, such as artesunate, have a short half-life and very rapid anti-malarial activity. Theoretically, using such agents in conjunction with well-established anti-malarial drugs such as sulfadoxine-pyrimethamine may reduce the rate of drug resistance. Such a combination has not previously been used in Africa. We have conducted a pilot safety trial of artesunate (4 mg/kg for 3 days) given with a single dose of sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine) compared to sulfadoxine-pyrimethamine alone among 40 Gambian children with uncomplicated malaria. Both regimens were safe and well tolerated and there were no adverse experiences attributed to the combination. The addition of artesunate resulted in a higher proportion of afebrile children and children with a negative blood film on Day 2, and a reduction in the proportion of gametocyte carriers, when compared to sulfadoxine-pyrimethamine alone.
青蒿素衍生物，如青蒿琥酯，半衰期短且抗疟活性非常迅速。从理论上讲，将此类药物与已确立的抗疟药物如磺胺多辛-乙胺嘧啶联合使用，可能会降低耐药率。此前这种联合用药在非洲尚未使用过。我们在40名患有单纯性疟疾的冈比亚儿童中进行了一项试点安全性试验，将青蒿琥酯（4毫克/千克，连用3天）与单剂量的磺胺多辛-乙胺嘧啶（25毫克/千克磺胺多辛）联合使用，并与单独使用磺胺多辛-乙胺嘧啶进行比较。两种治疗方案均安全且耐受性良好，未发现因联合用药导致的不良事件。与单独使用磺胺多辛-乙胺嘧啶相比，加用青蒿琥酯导致在第2天体温正常的儿童和血涂片阴性的儿童比例更高，并且配子体携带者比例降低。
